Samapika Ray1, Niloy Roy1, Biraj Kumar Barman2, Paramita Karmakar1, Pranish Bomzan1, Biplab Rajbanshi1, Vikas Kumar Dakua3, Ankita Dutta4, Anoop Kumar4, Mahendra Nath Roy1,3. 1. University of North Bengal, Department of Chemistry, Raja Rammohanpur, Darjeeling, West Bengal, India 734013. 2. Parimal Mitra Smriti Mahavidyalaya, Department of Chemistry, Malbazar Jalpaiguri, West Bengal, India 735221. 3. Alipurduar University, Department of Chemistry, Alipurduar, West Bengal, India 736122. 4. University of North Bengal, Department of Biotechnology, Raja Rammohanpur, Darjeeling, West Bengal, India 734013.
Abstract
Our present study intended to investigate the encapsulation of DL-AGT within the lipophilic cavity of a β-CD molecule. The consequential inclusion system was characterized by UV-visible spectroscopy and 1H NMR, PXRD, SEM, and FT-IR studies. Molecular docking was performed for the inclusion complex to discover the most proper orientation, and it was seen that the drug DL-AGT fits into the cavity of β-CD in a 1:1 ratio, which was also confirmed from the Job plot. Furthermore, a comparison was done on the basis of cell viability between the drug and its inclusion complex.
Our present study intended to investigate the encapsulation of DL-AGT within the lipophilic cavity of a β-CD molecule. The consequential inclusion system was characterized by UV-visible spectroscopy and 1H NMR, PXRD, SEM, and FT-IR studies. Molecular docking was performed for the inclusion complex to discover the most proper orientation, and it was seen that the drug DL-AGT fits into the cavity of β-CD in a 1:1 ratio, which was also confirmed from the Job plot. Furthermore, a comparison was done on the basis of cell viability between the drug and its inclusion complex.
The
drug dl-aminoglutethimide, (±)-3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
(DL-AGT) (Scheme ),
used as an aromatase inhibitor for the treatment of advanced breast
cancer and Cushing’s syndrome was chosen as a suitable guest
molecule for this study. According to the Biopharmaceutics Classication
System, it is a class 11 drug with low water solubility but good permeability.[1]dl-Aminoglutethimide can cause aromatase
inhibition. It was initially introduced as an anticonvulsant but due
to its side effects of acting as a potent inhibitor of several enzymes
on the adrenal cortex, it was no longer used. These drawbacks of this
drug changed into a clinical advantage in the treatment of Cushing’s
syndrome and advanced breast cancer. The growth of certain tumors
depends on specific hormones, and that makes the basis of endrocrine
therapy of breast cancer. DL-AGT is found to be effective in hormone-dependent
breast carcinoma by suppressing the estrogen level in post-menopausal
women. It inhibits the conversion of androgen to estrogen.[2] Moreover this drug is very effective in painful
bone metastasis. However, aminoglutethimide has its side effects because
of its toxicity,[3] such as lethargy, depression,
and rash, in addition to its benefits.[4]
Scheme 1
Structures of the Studied Molecules
Currently, molecular encapsulation is an important strategy to
increase the bioavailability of certain drugs to retain their therapeutic
activity. Potent drug delivery systems including biocompatible polymersand
nanoparticles have already been explored. Cyclodextrin-based drug
delivery systems are found to be the most prominent and reliable due
to their nontoxicity and biodegradability.[5,6] Cyclodextrins
or cycloamyloses are polymers with a truncated-cone-shaped cavity
having a minimum number of six D(+)-glucopyranose units linked
through α-1,4-bonds (Scheme ).[7] They can be natural
or semisynthetic (oligosaccharides).[8] The
α-, β-, and γ-cyclodextrins and their derivatives
have been extensively used in pharmaceutical science. For parental
drug delivery, with oral administration, cyclodextrins have been extensively
used. The applications of CDs are even more numerous than those above,
as they are able to make inclusion complexes with some specific molecules
which will fit in the cavity. Thus, the size of the entering guest
molecule is also an important parameter here.[9] The interactions between the host and the guest molecules are mainly
noncovalent: e.g., ion–dipole, hydrogen-bonding and van der
Waals types. The most widely accepted host for complex formation is
β-CD due to its suitable cavity diameter and low production
cost.[10,11] β-Cyclodextrin consists of seven α-d-glucopyranose units joined by α-1,4-linkages.[12] Cyclodextrins are able to modify the pharmacological
properties of the encapsulated active substances such as solubility,
bioavailability, chemical stability, dispersibility, and toxicity;
thus, by the preparation of inclusion complexes with cyclodextrin
molecules it can be possible to enhance or improve such properties
of the active compounds.[13−16]In our present work, encapsulation of dl-aminoglutethimide
within the nanocavity of β-cyclodextrin was established by UV–vis,
IR spectroscopic, powder X-ray diffraction, 1H NMR, 2D
ROESY, and scanning electron microscopic studies. A Job plot implies
the stoichiometry of the complex to be 1:1, and a UV–visible
study has given a proper explanation of the thermodynamic parameters
of the inclusion process and association constant of the complex.
Furthermore, an in vitro cell viability study between
the drug and the inclusion complex showed that the inclusion complex
is less toxic to a human normal kidney cell line in comparison to
the drug. By the process of inclusion we are aiming toward the improvement
of the properties of the drug (DL-AGT), i.e. to increase its solubility
as it has low solubility, an enhancement of the specificity, and reduction
of the toxicity. Most notably, the stability constant for the complexation
of DL-AGT and β-CD by UV–visible spectroscopy has already
been determined in the literature, though the whole project was on
TM-β-CD and DL-AGT inclusion phenomena (Scheme ).[17]
Scheme 2
Plausible
Mechanism of Inclusion
Results and Discussion
Job Plot
The stoichiometry
of the
host–guest inclusion complex can be determined with the help
of a continuous variation method or a Job method.[18] Here, a set of solutions of the drug (DL-AGT) and β-CD
was prepared by varying the mole fraction of DL-AGT from 0 to 1, and
by UV–vis spectroscopy the absorbances of all the solutions
were checked at the λmax value (238 nm). By plotting
ΔA × R against R, s Job plot is generated, where ΔA is the difference in absorbances of the guest without and with β-CD
and R = [DL-AGT]/[DL-AGT+β-CD]. The Rmax value obtained from the Job plot is 0.5
(Figure a), which
signifies a 1:1 complexation of the guest and host molecule.[19]
Figure 1
(a) Job plot for the stoichiometry 1:1 (host:guest) and
(b) spectra
of the Job plot.
(a) Job plot for the stoichiometry 1:1 (host:guest) and
(b) spectra
of the Job plot.
Association
Constants and Thermodynamic Parameters
The association constants
of DL-AGT and β-CD IC were calculated
at three different temperatures by UV–vis spectroscopy, measuring
the change in the molar extinction coefficient of the guest molecule
when it enters into the hydrophobic cavity of β-CD from the
hydrophilic environment. The absorbance changes of DL-AGT were studied
by gradually increasing the concentration of β-CD. The Benesi–Hildebrand
equation is used for the determination of association constant[18]where [AGT] and [CD] are the
concentrations of the guest molecule and the cyclodextrin molecule,
Δε refers to the change in the molar extinction coefficient,
and ΔA is the change in the absorbance of DL-AGT on addition
of CD. From the double-reciprocal plot of the Benesi–Hildebrand
equation we have calculated the association constants at three different
temperatures (293.15, 303.15, and 313.15 K), and the linearity of
the plot suggests a 1:1 stoichiometry of the host and guest molecules.[20]Furthermore, the important thermodynamic
parameters are determined from the plot of log ka vs 1/T using eq .The spontaneity of the reaction,
i.e. the free energy change, is determined by eq where the symbols have their usual significance.
Now the values of thermodynamic parameters suggest that the process
of inclusion is exothermic, spontaneous, and entropy restricted (Table ). This restriction
in entropy may be due to the molecular association between the guest
and host molecules.[21]
Table 1
Association Constants (ka), Gibbs Free
Energy (ΔG°),
Enthalpy (ΔH°) and Entropy (ΔS°) of an AGT-β-CD System from UV–Vis
Spectroscopy
ka (103 M–1)
complex
293.15 K
303.15 K
313.15 K
ΔG° (kJ mol–1)
ΔH° (kJ mol–1)
ΔS° (J mol–1) K–1
DL-AGT·β-CD
3.55
2.54
1.59
–19.81
–30.59
–36.16
Solubility Study of DL-AGT·β-CD
Inclusion Complex
The ethanolic solubility between pure DL-AGT
and the DL-AGT·β-CD inclusion complex was evaluated using
UV–visible spectroscopy.[22] The UV–visible
spectra of the DL-AGT·β-CD inclusion complex at different
concentrations in ethanolic solutions are shown in Figure . As DL-AGT is sparingly soluble
in water, the experiment was set up in the ethanolic phase and the
solubility of DL-AGT in ethanol was greatly enhanced when the DL-AGT·β-CD
inclusion complex was formed. DL-AGT displayed a maximum absorption
peak (λmax) at about 238 nm in the inclusion complex,
as shown in Figure A, and all of the calculations were carried out using the λmax value. It has been found that the peak positions during
titration were independent of the concentrations of DL-AGT·β-CD
but peak intensities increased upon an increase in concentration.
The plot of the absorbance of DL-AGT·β-CD at 238 nm vs
the concentration of DL-AGT·β-CD provides a straight line
as shown in Figure B. According to the Lambert–Beer law, the molar extinction
coefficient (ε) of DL-AGT·β-CD in ethanolic solution
was evaluated to be 0.0907 L g–1cm–1. The UV spectrum of the DL-AGT·β-CD inclusion complex
at a saturated concentration in ethanolic solution is shown in the Figure S5, from which the absorbance value of
a saturated solution of the DL-AGT·β-CD inclusion complex
was calculated and found to be 1.59873. Finally, the solubilities
of pure DL-AGT and DL-AGT·β-CD in ethanol at 25 °C
are shown in the Table S5. Therefore, it
was clear from the Table S5 that the DL-AGT·β-CD
inclusion complex has greater a solubility of 17.62 mg mL–1 in comparison to that of pure DL-AGT of 7 mg mL–1. These results clearly imply that the water-soluble host β-CD
played a critical role in remarkably improving the solubility of the
less soluble DL-AGT by the formation of the DL-AGT·β-CD
inclusion complex. From the above we can also get a clear idea about
the solubility of DL-AGT, as there was an enhancement in solubility
in ethanol after inclusion.[23]
Figure 2
(A) UV spectra
of DL-AGT·β-CD with different concentrations
(g L–1) in ethanolic solutions (at 298.15 K): (a)
0.033; (b) 0.066; (c) 0.099; (d) 0.132; (e) 0.165; (f) 0.198; (g)
0.228. (B) Plot of the absorbance of DL-AGT·β-CD at 238
nm vs the concentration of DL-AGT·β-CD.
(A) UV spectra
of DL-AGT·β-CD with different concentrations
(g L–1) in ethanolic solutions (at 298.15 K): (a)
0.033; (b) 0.066; (c) 0.099; (d) 0.132; (e) 0.165; (f) 0.198; (g)
0.228. (B) Plot of the absorbance of DL-AGT·β-CD at 238
nm vs the concentration of DL-AGT·β-CD.
PXRD Study
A diffractogram (Figure ) of the DL-AGT·β-CD
complex shows the disappearance of some of the pure DL-AGT spectral
lines at 2θ values of 12.38, 15.09, 16.75, 17.95, and 24.92°
and the β-CD spectral lines at 2θ values of 4.63, 9.11,
and 12.63°, as shown in Table . Additionally, the appearance of new spectral lines
of DL-AGT·β-CD complex at 2θ values of 17.85 and
18.50° is observed with less intense peaks. It is well-known
that the peak at 2θ = ∼20° in cyclodextrin-based
inclusion complexes is a characteristic of “channel-type”
packaging in β-CD where only the head-to-head arrangement has
been observed. The disappearance of some peaks and the generation
of new peaks with less intensity in the spectra of DL-AGT·β-CD
inclusion complex suggest some types of interactions between the guest
and host molecules.
Figure 3
PXRD diffractograms
of (a) β-CD, (b) DL-AGT, and (c) DL-AGT·β-CD
IC (inclusion complex).
Table 2
2θ Values of
β-CD, DL-AGT,
and DL-AGT·β-CD Inclusion Complex from PXRD Study
component
2θ
(deg)
β-CD
4.63, 9.11, 12.63
DL-AGT
12.38, 15.09, 16.75, 17.95,
24.92
DL-AGT·β-CD IC
17.85, 18.50
PXRD diffractograms
of (a) β-CD, (b) DL-AGT, and (c) DL-AGT·β-CD
IC (inclusion complex).
FT-IR
Spectroscopy
The formation
of an inclusion complex can also be explained with the help of FT-IR
spectroscopy. It is important to note that, when the inclusion complex
is formed, several characteristic peaks of the guest molecule might
shift, reduce, or disappear. The stretching and bending vibrations
of the three components, viz. DL-AGT, β-CD, and their IC are
shown in Figure .
Figure 4
Infrared
spectra of (a) β-CD, (b) DL-AGT, and (c) DL-AGT·β-CD
IC (inclusion complex).
Infrared
spectra of (a) β-CD, (b) DL-AGT, and (c) DL-AGT·β-CD
IC (inclusion complex).In the case of DL-AGT,
the most important bands present in the
IR spectrum are those related to the imide and amino functional groups.
The N–H, C–H, C–O, and C–N stretching
modes give strong bands situated at 3500–3200, 2964, 1687,
and 1202 cm–1, respectively The stretching at 3467
and 3375 cm–1 may be due to the 1° and 2°
amines, respectively, present in the drug molecule. The aromatic C=C
stretching vibrations for DL-AGT were found at 1625, 1515, and 1448
cm–1. Bending vibrations of −NH and −NH2 appearing at 1625 cm–1 display strong bands
in the IR spectrum. However, in β-CD, the O–H stretching
vibration appeared at 3424 cm–1. The C–H
stretching frequency for β-CD appeared at 2921 cm–1, and the bending vibration of C–O–C in β-CD
appeared at 1153 cm–1. When, the inclusion complex
is formed, a broad hump is observed at 3388 cm–1. The characteristic peak for C=O was observed at 1687 cm–1 in the case of DL-AGT, which was slightly shifted
to 1693 cm–1 in the IC. In addition, the aromatic
C=C stretching vibrations for DL-AGT in the complex were shifted
to 1632, 1515, and 1454 cm–1 and the peak intensities
were reduced to some extent. Thus, from the above explanation and
from Figure , it is
worth noting that most of the signals of β-CD and DL-AGT have
been highly shifted with less peak intensity in the inclusion complex,
implying some nonbonding interactions of the guest and host in the
inclusion complex.
1H NMR Study
To predict
the structure of the inclusion complex, 1H NMR spectroscopy
is a very useful method. It delivers detailed information about the
positions of the H nuclei present in the structure of the molecule/complex
of concern. As the host–guest inclusion process is based on
weak nonbonding interactions, the changes occurring in the chemical
shift values after inclusion are comparatively smaller than in other
cases.[24]In β-CD, the H3 and
H5 protons are located inside the cavity (H3 close to the wider rim
and H5 close to the narrower rim) and H6 is outside the cavity, near
the narrower rim.[25] When the guest molecule
enters the cavity of β-CD, the protons inside the cavity (H3,
H5) would definitely show some changes in chemical shift from that
before.[26] It is observed that after inclusion
the H3 and H5 protons of β-CD were shifted upfield but to a
smaller extent.The 1H NMR spectra of DL-AGT, β-CD,
and the inclusion complex were shown in Figure . Numerous peaks were found in the spectrum
of DL-AGT as well as in β-CD, which are given in Table . Chemical shift changes were
calculated from the inclusion complex with respect to both β-CD
as well as DL-AGT as Δσ = σcomplex –
σDL-AGT/β-CD). In case of β-CD, the upfield shift
is greater for H3 (−0.04 ppm) than for H5 (−0.02 ppm).
This result indicates that the inclusion occurred through the wider
rim and that the H3 proton shifted more upfield than in comparison
to the H5 proton. The signals related to the aromatic protons (H6′,
H7′) of AGT remain almost constant in the spectrum of the inclusion
complex. However, all the protons related to the piperidine-2,6-dione
moiety (H2′, H3′, H4′, H5′) are shifted
upfield, as is shown in Table . Therefore, it can be concluded that only the nonaromatic
parts were incorporated in the cavity of β-CD after complexation.
Figure 5
1H NMR spectra of (a) DL-AGT, (b) β-CD, and (c)
DL-AGT·β-CD IC.
Table 3
Chemical Shifts and Their Deviations
for the Protons of β-CD and of DL-AGT in Free State and in an
Inclusion Complex
chemical
shift σ (ppm)
proton
β-CD
DL-AGT
DL-AGT·β-CD
Δσ (σcomplex – σfree)a
H3
3.70
3.66
–0.04
H5
3.58
3.56
–0.02
H2′
5.11
5.07
–0.04
H3′
2.08
2.05
–0.03
H4′
1.81
1.78
–0.03
H5′
0.75
0.73
–0.02
H6′
6.93
6.93
0.0
H7′
6.55
6.55
0.0
Ar-NH2
10.73
10.73
0.0
Negative values of Δσ
indicate upfield shifts.
Negative values of Δσ
indicate upfield shifts.1H NMR spectra of (a) DL-AGT, (b) β-CD, and (c)
DL-AGT·β-CD IC.It is also evident from the MD studies that the aromatic part of
DL-AGT is stabilized at the narrower end of the β-CD cavity.
This is perhaps the reason for the absence of shifting of the aromatic
protons of DL-AGT.
2D-ROESY NMR Study
Two-dimensional
(2D) NMR spectroscopy provides important information about the spatial
arrangement between host and guest atoms by an observation of intermolecular
dipolar cross correlations. If two protons are closely located in
space, i.e., closer than 0.4 nm, this can produce a nuclear Overhauser
effect (NOE) cross correlation in two-dimensional rotating-frame nuclear
Overhauser enhancement correlation (2D-ROESY) spectroscopy, and therefore
cross peaks in ROESY spectra will be obtained. The ROESY spectrum
of the DL-AGT·β-CD complex (Figure ) showed appreciable correlations of the
H-3′ and H-5′ protons of DL-AGT with the H-3 and H-5
protons of β-CD. These results indicate that the piperidine-2,6-dione
moiety of DL-AGT is in close proximity with the H-3 protons of β-CD.
These results further confirmed that the DL-AGT·β-CD inclusion
complex was successfully formed in the solution phase.
Figure 6
ROESY spectrum of β-CD.DL-AGT
IC in d6-DMSO.
ROESY spectrum of β-CD.DL-AGT
IC in d6-DMSO.
Molecular Docking Study
Molecular
docking gives us effective information about bond simulations between
molecules.[27] In order to comprehend the
orientation, conformation, and interaction of the drug/guest molecule
within the cavity of β-CD, molecular modeling is a constructive
computational technique.[28]Here,
docking has been used to predict the possible bound conformation of
DL-AGT·β-CD inclusion complex and to estimate the binding
affinity.[27] The drug within the binding
cavity of β-CD was docked, and the most probable binding conformation
was obtained.[6] The results showed that
the interaction between DL-AGT and β-CD is 1:1. The drug fit
comfortably within the pocket, as shown in Figure . The binding affinity for DL-AGT and β-CD
was found to be −23.012 kJ/mol, as given in Table , which is in good agreement
with the experimental findings from UV–vis spectroscopy. The
results also indicated that in the complex only the piperidine-2,6-dione
moiety of AGT interacted with the H-3 protons of the CD cavity. The
findings of this theoretical study are consistent with the results
of FTIR and NMR experiments.
Figure 7
Mode of binding of the drug DL-AGT into β-CD
(IC): (a) top
view; (b) side view.
Table 4
Binding
Affinity of DL-AGT and β-CD
from Molecular Docking
ligand with
receptor
binding affinity
(ΔG° (kJ/mol))
DL-AGT-β-CD (IC)
–23.012
Mode of binding of the drug DL-AGT into β-CD
(IC): (a) top
view; (b) side view.
SEM Study
Scanning electron microscopy
is one of the best techniques in describing the surface morphology
of different chemical entities in the solid state. The surface morphologies
of the host and guest and their inclusion complex are shown in Figure . Both DL-AGT and
β-CD were found in crystal form in different sizes. However,
DL-AGT appears as irregular-shaped crystal particles with large dimensions
(Figure A), whereas
β-CD has a polyhedral crystal like structure (Figure B). When complexation occurs,
it is evident that the DL-AGT·β-CD IC (Figure C) exhibits a different surface
morphology: a threadlike structure. This distinct surface morphology
may be due to the formation of the inclusion complex.[21] The totally dissimilar surface morphology of the inclusion
complex may assist the other experimental observations.
Figure 8
SEM images
of (A) DL-AGT (B) β-CD and (C) DL-AGT·β-CD
IC.
SEM images
of (A) DL-AGT (B) β-CD and (C) DL-AGT·β-CD
IC.
In Vitro Cell Viability
Study
The synthesized inclusion complex of the drug DL-AGT
and β-CD and the drug itself were evaluated for a cell viability
study. The cells were exposed to varying concentrations of the drug
and inclusion complex, and the results of the cell viability obtained
in the study are depicted graphically in Figure . After the drug treatment, the cell viability
was found to be concentration dependent. In the case of the drug,
as concentration increases, the cell viability of normal kidney cells
decreases. However, the cells are more viable in the presence of the
inclusion complex in comparison with the drug. This might be because
of the higher toxicity of the drug (DL-AGT) at higher concentration
(as the amount of the drug increases), where normal cells lose their
reproducibility and eventually die. However, for the inclusion complex
the cell viability is greater than that of the original drug as we
move from lower to higher concentration. Thus, it is worth mentioning
that the complex is less toxic in nature than the drug itself and
so the cells are able to grow and reproduce properly. This finding
clearly indicates the fact that the inclusion complex is less toxic,
as it causes less antiproliferative activity of cell in comparison
to the drug. This behavior of the inclusion complex might be due to
the controlled release of the drug from the cavity of β-CD.[14]
Figure 9
In vitro cell viability study of pure
drug and
its inclusion complex.
In vitro cell viability study of pure
drug and
its inclusion complex.
Conclusion
In our present study we have synthesized
an attainable inclusion
complex of the aromatase inhibitory drug DL-AGT and the host β-CD.
The process of inclusion was confirmed by 1H NMR, PXRD,
FTIR, SEM, and UV–vis studies. From the Job plot (UV–visible
study) and from the shifting of the H3 and H5 protons of β-CD
in the 1H NMR spectra of the IC, it is confirmed that the
inclusion occurred in a 1:1 stoichiometric ratio. Moreover, the solubility
of the IC in ethanol being greater than that of the pure drug was
also determined. The above experimental observations were further
affirmed by a molecular docking study, which helps to predict the
most stable conformation of the inclusion complex. Finally, a cell
viability study between the drug and its IC with β-CD implies
that, when the concentration is increased, the inclusion complex shows
less toxicity than the drug itself. Thus, this is an important finding
about the inclusion complex of the drug with β-CD, which may
improve the therapeutic activity of the drug toward the application
it is meant for and also could change the path of science to a new
direction.
Experimental Section
Materials
The drug DL-AGT (purity
>98%, molecular weight 232.28 g/mol) was purchased from TCI chemicals
India PVT. Ltd. β-CD (purity ≥97%; molecular weight 1134.98
g/mol) was purchased from Sigma-Aldrich Germany. All reagents were
used without further purification.
Methods
dl-Aminoglutemide
and β-CD were weighed using a Mettler Toledo AG-285 apparatus
(uncertainty ±0.1 mg), and they were prepared in a 15% acetonitrile
solution (acetonitrile–water mixture) at 298.15 K. Other solutions
of the required strengths were prepared by mass dilution.Fourier
transform infrared (FTIR) spectra of DL-AGT, β-CD, and the DL-AGT·β-CD
inclusion complex were recorded on a PerkinElmer 8300 FT-IR spectrometer
(PerkinElmer, Inc., Germany) using the KBr disk technique. Samples
were prepared as thin KBr disks using a 1:100 ratio of sample to KBr.
The range of scanning was kept at 4000–400 cm–1. 1H NMR spectra were obtained using a Bruker AVANCE NEO
400 MHz (Bruker Inc., Germany) instrument in DMSO-d6 solvent medium, where the solvent residual peak was
taken as an internal standard. UV–visible titration for the
Job plot as well as the determination of the association constant
were carried out with an Agilent 8453 spectrophotometer (USA). PXRD
data were obtained with Bruker D8 Advance instrument (Germany) having
a Cu Kα radiation source with 45 kV and λ = 1.5406 Å,
and the scanning range was from 5° to 80°. The scanning
electron micrographs were determined with JEOL JSM-IT 100 scanning
electron microscope.
Molecular Docking
A molecular docking
process was employed through PyRx software for the virtual screening
of the small guest molecule (DL-AGT) and the host (β-CD) to
find the geometry of the inclusion complex.[29] This software is written in the Python programming language with
an in-built user interface that can be easily operated on all major
operating systems (Linux, Windows, and Mac OS) and used to determine
the binding parameters as well as binding geometry. PyRx uses Vina
and AutoDock 4.2 as docking software. The input files for the host
and guest were initially in the. pdb format and changed to .pdbqt
files using in-built AutoDock Vina software. Once all the files were
prepared, they were subjected to docking by means of AutoDock Vina.
Before the docking calculation was started, a grid box was prepared
around the host molecule. This resulted in a binding site centers
of 8.3636, 24.4146, and 1.2278 for the x, y, and z axes, respectively. Grid box dimensions
for the x, y, and z conformations were fixed at 25, 25, and 25, respectively. The grid
space size was allocated perfectly, which allows selecting a search
space for the host to perform docking with the guest, normally, at
the most probable binding site. The interaction between DL-AGT and
β-CD was determined on the basis of the Lamarckian genetic algorithm
(LGA). Once the calculations were ended, the binding affinity (kJ
mol–1) of the most stable conformation of the host
with the guest was provided by the software and is given in Table .[30]
In Vitro Cell Viability Study
The cell viability study of the drug
and the synthesized complex
was investigated by an MTT assay. HEK-293 (human normal kidney cell
line) was cultured in a 96-well microtiter plate at 37 °C, in
the presence of 5% carbon dioxide (CO2), at a density of
5 × 103 cells/well in 100 μL of DMEM (Dulbecco’s
Modified Eagle Medium) Ham F-12 culture medium. After 24 h of incubation,
the drugs (DL-AGT, DL-AGT·β-CD) were added in each well
at different concentrations (50, 100, 150, 200, 250, 300, 350, 400,
450, and 500 μM) in triplicate. Then, the microtiter plate was
incubated under the same experimental conditions. The next day, after
the culture media were discarded from the treated plate 10 μL
(5 mg/mL) of MTT powder (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) dissolved in 1X PBS was added to each well. The plate was
again kept in the incubator for 3 h under the aforementioned conditions.
Finally, a formazan solubilizer, i.e. isopropanol, was added to each
well containing MTT solution and the plate was shaken for about 10
min. Finally, the absorbance was recorded by a microtiter plate reader
(SPECTROstarNano, Germany) at 620 nm.[31] Solutions of the samples were prepared in DMSO.[32]
Preparation of Inclusion
Complex
By mixing β-CD and DL-ADT in a molar ratio
of 1:1, the IC was
prepared. A 1.0 mmol portion of DL-AGT was dissolved in 25 mL of 15%
acetonitrile and 1.0 mmol of β-CD in 25 mL of distilled water.
While the β-CD solution was kept on a magnetic stirrer, the
DL-AGT guest solution was added slowly and the mixture was stirred
for 36 h at constant temperature of 50 °C. The suspension thus
obtained was filtered and dried in an oven at 70 °C for 7 h.
Ultimately the solid powder was collected and stored in a desiccator
for future use.
Authors: Tatyana R Usacheva; Vitaly A Volynkin; Viktor T Panyushkin; Dmitry A Lindt; Thi Lan Pham; Thi Thu Ha Nguyen; Thi My Hanh Le; Diana A Alister; Dzhovidon N Kabirov; Natalya N Kuranova; George A Gamov; Roman A Kushnir; Marco Biondi; Concetta Giancola; Valentin A Sharnin Journal: Molecules Date: 2021-07-21 Impact factor: 4.411